Oral Sildenafil and Intravenous Milrinone on Postoperative Pulmonary Hypertension
Pulmonary Hypertension
About this trial
This is an interventional treatment trial for Pulmonary Hypertension focused on measuring pediatric, cardiac, sildenfil, milrinone, pulmonary hypertension
Eligibility Criteria
Inclusion Criteria:
- Thirty patients in the age range 2-24 months scheduled for surgical closure of ventricular septal defect (VSD) associated with postoperative pulmonary hypertension [diagnosed in all patients by preoperative echocardiography and confirmed invasively by the pulmonary catheter before transfer to ICU by Mean Pulmonary Arterial Pressure (MPAP) > 25 mmHg or Mean Pulmonary Arterial Pressure (MPAP) /Mean Systemic Arterial Pressure (MAP) > 0.33] were enrolled in this study.
Exclusion Criteria:
- Patients with pre-existing obstructive lung disease, mitral valve disease, left ventricular dysfunction, and patients receiving preoperative pulmonary vasodilators
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
milrinone group
sildenafil and milrinone group
milrinone
milrinone and sildenafil